26-30 bp dsRNA Duplexes for Potent Gene Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA interference (RNAi) methods face challenges in achieving high potency and duration of action while minimizing 'off-target effects' due to limitations in siRNA molecule design and concentration requirements, leading to inefficient gene silencing in mammalian cells.
Innovation Solution
The development of double-stranded RNA (dsRNA) compositions that are processed in vivo to produce active siRNAs, specifically designed with lengths and structural features such as 26-30 nucleotide sequences, 3' overhangs, and modified ends to enhance processing by Dicer, thereby increasing potency and duration of RNAi effects while reducing off-target interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If long dsRNA (150 bp or greater) is used to induce RNA interference in Drosophila cells, then RNA interference activity is activated, but the dsRNA is degraded by Dicer into short siRNA duplexes requiring complex processing
Solution Approach 1:
The patent segments long dsRNA into shorter dsRNA duplexes of 26-30 base pairs that directly activate RNA interference without requiring Dicer processing. This segmentation eliminates the need for enzymatic cleavage while maintaining RNAi activity, resolving the contradiction between achieving RNAi effects and avoiding complex processing requirements
Solution Approach 2:
The patent performs preliminary processing of dsRNA in vitro to generate optimally sized 26-30 bp duplexes with specific structural features (2-base 3' overhangs) before introduction into cells. This preliminary action eliminates the need for intracellular Dicer processing, directly achieving RNAi activation without the complexity of in vivo processing
2Object-affected harmful factors
If short chemically synthesized siRNA duplexes (21-23 bp) are used to suppress gene expression in mammalian cells, then interferon responses are avoided, but potency and duration of action are limited
Solution Approach 1:
The patent changes the length parameter of dsRNA from the conventional 21-23 bp siRNA size to 26-30 bp duplexes with 2-base 3' overhangs. This parameter change optimizes both stability and RNAi activity in mammalian cells, achieving prolonged duration of action while maintaining avoidance of interferon responses
Solution Approach 2:
The patent creates composite dsRNA structures combining optimal duplex region (21-23 bp) with structured overhangs (2 bases at 3' end). This composite structure integrates the stability of longer RNAs with the RNAi activity of short siRNAs, achieving enhanced potency and duration without triggering interferon responses
3Productivity
If higher concentrations of siRNA are used to increase RNAi potency, then gene silencing efficiency improves, but off-target effects increase
Solution Approach 1:
The patent changes the structural parameters of RNAi effectors to 26-30 bp duplexes with specific 2-base 3' overhangs, which enhances potency at lower concentrations. This parameter change allows achieving high gene silencing efficiency without requiring high concentrations that would cause off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA compositions demonstrate enhanced potency and prolonged RNAi activity, effectively silencing target genes with reduced off-target effects, allowing for more precise gene regulation and extended duration of action compared to traditional siRNA approaches.
Implementation Method 1
long dsRNAs are degraded by an RNase III class enzyme called Dicer (Bernstein et al., 2001) into very short 21-23 bp duplexes that have 2-base 3′-overhangs
Implementation Method 2
The antisense strand of the siRNA duplex serves as a sequence-specific guide that directs activity of an endoribonuclease function in the RNA induced silencing complex (RISC) to degrade target mRNA
Implementation Method 3
the protein kinase PKR is activated by dsRNAs of greater than 30 bp long (Manche et al., 1992) and results in phosphorylation of translation initiation factor eIF2α
Implementation Method 4
activation of 2′5′-oligoadenylate synthetase (2′-5′-OAS), which leads to RNA degradation (Minks et al., 1979)
Data Source
AI summary
The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.